The Cooper Companies

CooperCompanies 4-for-1 Stock Split Effective Friday (2/16)

Retrieved on: 
Thursday, February 15, 2024

SAN RAMON, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced that its four-for-one stock split will become effective on Friday, February 16, 2024, at 5:00 PM ET, and trading is expected to begin on a stock split-adjusted basis at market open on Tuesday, February 20, 2024, under the existing trading symbol “COO”.

Key Points: 
  • SAN RAMON, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced that its four-for-one stock split will become effective on Friday, February 16, 2024, at 5:00 PM ET, and trading is expected to begin on a stock split-adjusted basis at market open on Tuesday, February 20, 2024, under the existing trading symbol “COO”.
  • The stock split supports Cooper’s desire to make ownership of its stock more accessible to employees and investors.
  • Cooper previously announced on its fourth quarter 2023 earnings release dated December 7, 2023, that it would implement the stock split of its outstanding shares of common stock, as approved by its board of directors.
  • The new CUSIP number for Cooper’s common stock following the split will be 216648501.

SightGlass Vision Receives Breakthrough Device Designation from U.S. Food and Drug Administration

Retrieved on: 
Wednesday, February 14, 2024

LOS ALTOS, Calif., Feb. 14, 2024 /PRNewswire/ -- SightGlass Vision, a joint venture of CooperCompanies and EssilorLuxottica that develops innovative technologies and science-based treatments to address the global myopia epidemic, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its Diffusion Optics Technology™ (DOT™) spectacle lenses, which are intended to slow myopia progression in children. The unique design is the first to use the contrast management mechanism of action, incorporating thousands of elements that gently scatter light across the retina.

Key Points: 
  • The FDA's Breakthrough Devices Program is for highly innovative devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions.
  • Manufacturers are given more frequent opportunities for FDA feedback during the premarket review phase, as well as a prioritized submission review.
  • Since the program's introduction in 2015, only 18 other ophthalmic devices have received the Breakthrough Device designation.
  • *
    "The FDA Breakthrough Device designation for Diffusion Optics Technology™ (DOT™) spectacle lenses is a milestone for our organization—and for the broader fight against the pediatric myopia epidemic.

Former CooperVision Leader Tom Bender Joins MediPrint Ophthalmics as Strategic Advisor

Retrieved on: 
Tuesday, February 13, 2024

MediPrint Ophthalmics , a clinical stage ophthalmic company focused on transforming the delivery of ophthalmic pharmaceuticals, today proudly announced the appointment of Thomas Bender as a strategic advisor.

Key Points: 
  • MediPrint Ophthalmics , a clinical stage ophthalmic company focused on transforming the delivery of ophthalmic pharmaceuticals, today proudly announced the appointment of Thomas Bender as a strategic advisor.
  • Mr. Praful Doshi, CEO and Founder of MediPrint Ophthalmics , welcomed the new addition, stating, "Tom Bender's appointment marks a defining moment for our company.
  • His exceptional leadership transformed CooperVision into a global market leader, and we anticipate his insights will greatly progress our strategic initiatives and operational excellence."
  • Mr. Bender served as CEO of CooperVision from 1991 until his retirement as CEO in 2007, continuing as Chairman until 2021.

Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing

Retrieved on: 
Friday, February 9, 2024

‍TRUMBULL, Conn. and EL MONTE, Calif., Feb. 9, 2024 /PRNewswire/ -- CooperSurgical®, a global leader in fertility and women's health, and Fulgent Genetics, Inc. (NASDAQ: FLGT), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that they have partnered to offer families of Cord Blood Registry® (CBR®) exclusive newborn genetic screening panels.

Key Points: 
  • CBR Portrait includes more than twice as many genes as CBR Snapshot and may identify more rare causes of these conditions.
  • CBR Landscape also includes a pharmacogenetic (PGx) component, which is a type of genetic testing that can determine how a person breaks down or metabolizes certain medications.
  • "Part of our mission is to use our resources and testing to improve the lives of those around us.
  • Newborn genetic analysis serves as an illustration of this commitment, as early intervention may significantly improve health outcomes for many of these conditions."

CooperCompanies Announces Release Date for First Quarter 2024

Retrieved on: 
Thursday, January 25, 2024

SAN RAMON, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced it will report first quarter 2024 financial results on Thursday, February 29, 2024, at 4:15 PM ET.

Key Points: 
  • SAN RAMON, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced it will report first quarter 2024 financial results on Thursday, February 29, 2024, at 4:15 PM ET.
  • Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments.
  • The dial-in number for the call is 800-715-9871 and the conference ID is 5337119.
  • A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com .

Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now Controlled by the World's 10 Largest Cord Blood Banking Operators - ResearchAndMarkets.com

Retrieved on: 
Monday, January 22, 2024

There are over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.

Key Points: 
  • There are over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.
  • Today, nearly all U.S. cord blood banks and approximately one-third of global cord blood banks offer cord tissue storage.
  • The vast majority of the global cord blood market is now controlled by the world's 10 largest cord blood banking operators.
  • It reveals the identities of companies offering cord blood storage, cord blood processing technologies, cord blood expansion technologies, and cord blood therapeutics on a global basis.

BillingPlatform Secures $90 Million Growth Equity Investment from FTV Capital

Retrieved on: 
Wednesday, January 24, 2024

DENVER, Jan. 24, 2024 /PRNewswire/ -- BillingPlatform, the enterprise revenue lifecycle management platform for today's innovative business models, today announced a $90 million growth equity investment from FTV Capital, a sector-focused growth equity investor with more than 25 years of experience in enterprise technology and services, financial services, and payments and transaction processing. The investment will fuel BillingPlatform's continued expansion in a $10 billion market that is growing more than 10% per year as enterprises increasingly turn to the company's comprehensive portfolio of solutions for the Office of the CFO that enable new revenue streams and go-to-market strategies, reduce revenue leakage and improve customer satisfaction.

Key Points: 
  • FTV Capital's investment comes as BillingPlatform recorded significant growth, customer wins, and industry analyst and award recognition last year.
  • FTV Capital brings a flexible funding approach and makes equity investments that align with the objectives of company management teams to accelerate growth and expansion.
  • With this funding, FTV Capital joins Columbia Capital as institutional investors with minority investments in BillingPlatform.
  • We're excited to embark on the next chapter of this journey in partnership with BillingPlatform and FTV," added Jason Booma, partner at Columbia Capital.

CooperCompanies to Present at the J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, December 21, 2023

SAN RAMON, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, will participate at the J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024.

Key Points: 
  • SAN RAMON, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, will participate at the J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024.
  • Al White, President and CEO, will represent the Company in a session scheduled to begin at 6:00 PM ET.
  • The webcast will be available to investors and other interested parties by accessing the CooperCompanies’ website at http://investor.coopercos.com .
  • A replay of the event will be available on the same webpage following its conclusion.

CooperCompanies Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, December 7, 2023

Cash provided by operations of $607.5 million offset by capital expenditures of $392.5 million resulted in free cash flow of $215.0 million.

Key Points: 
  • Cash provided by operations of $607.5 million offset by capital expenditures of $392.5 million resulted in free cash flow of $215.0 million.
  • The Company announced today that its board of directors has made the decision to end CooperCompanies' de minimis semi-annual dividend.
  • To supplement our financial results and guidance presented on a GAAP basis, we use non-GAAP measures that we believe are helpful in understanding our results.
  • We believe it is useful for investors to understand the effects of these items on our consolidated operating results.

CooperCompanies Appoints Lawrence E. Kurzius to Board of Directors

Retrieved on: 
Thursday, November 30, 2023

SAN RAMON, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) announced today that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023.

Key Points: 
  • SAN RAMON, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) announced today that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023.
  • Kurzius has also been appointed to serve on the Audit Committee and Organization & Compensation Committee when he joins the Board.
  • “We are thrilled to welcome Lawrence to our Board of Directors,” said Al White, President and CEO.
  • He currently serves as the Executive Chairman of the Board of Directors of McCormick and Company, and he is on the board of Elanco Animal Health Inc.